2026. Efficacy and safety outcomes from the MATISSE phase 3 trial of maternal bivalent RSVpreF vaccination among pregnant women vaccinated at 32 to 36 weeks of gestation. Swiss Medical Weekly. 156, 1 (Jan. 2026), 4711. DOI:https://doi.org/10.57187/4711.